¥84.2 Million, 84 Centers, $328 Million: Hengrui Took a Drug With No Story All the Way to Filing

On the Phase 3 results, there are currently two official statements.

The interim report dated August 20 states: “The company has completed the Phase 3 clinical study of HRG2010 in Parkinson’s disease; the results support its improvement of motor fluctuations, with good safety and tolerability.”

The August 24 acceptance announcement goes further: this was “China’s first Phase 3 confirmatory study in Parkinson’s patients using carbidopa/levodopa extended-release tablets as an active control (HRG2010-301)” — randomized, double-blind, double-dummy, multicenter, led by principal investigator Prof. Haibo Chen of Beijing Hospital, with 84 centers across China participating. The primary endpoint was the change from baseline in mean daily “off” time at the end of the double-blind treatment period; the key secondary endpoint was the change from baseline in mean daily “on” time without troublesome dyskinesia. The result: “Compared with the control group, HRG2010 capsules shortened off time and extended good on time in Parkinson’s patients with motor fluctuations, with efficacy maintained on long-term use. On safety, HRG2010 capsules were consistent with the known profile of levodopa combination drugs, with no new safety signals observed.”

So the accurate statement is: the positive direction and the qualitative conclusions are public; the effect size, p-values, and complete safety data are not. The announcement attributes this results summary to “compiled from study materials” — meaning it has not been through peer-reviewed publication. As of today, no results data for this study have been posted on clinical trial registries either.

The distinction matters. “Shortening off time” is a direction; by how many hours, by how much versus control, and whether it is statistically robust — those are what decide whether it can change prescribing habits. Until those numbers are out, any judgment of how good it is can only be conditional.

The cornerstone of Parkinson’s treatment is levodopa. The problem is its short half-life: by the mid-to-late stage of the disease, patients’ blood drug levels ride a roller coaster — when the drug is working it’s called “on” time; when it wears off and tremor and rigidity return, that’s “off” time. Clinically this is called motor fluctuation. China’s Parkinson’s Disease Treatment Guidelines (5th edition) state the management path plainly: increase dosing frequency and reduce the single dose without increasing the total daily dose, or switch to an extended-release formulation.

Translated: have the patient take the drug more times a day. Some patients dose five or six times daily — and have to time it one hour before or an hour and a half after meals.

That is exactly what HRG2010 aims to fix. In the interim report’s own words, it is “an innovative fixed-dose combination of carbidopa and levodopa with immediate-release and extended-release components” — one capsule carrying both an IR unit for fast onset and an ER unit to stretch the effect. In the acceptance announcement the company classifies it as a “Class 2 new drug” — the improved-new-drug category for chemical drugs.

Hengrui didn’t invent this idea, and says so candidly in its own announcement: marketed products of the same class at home and abroad mainly include carbidopa/levodopa extended-release tablets (brand name Sinemet) and Amneal’s RYTARY® and CREXONT®. Crexont won FDA approval on August 7, 2024; Amneal’s official press release describes it as “IR granules with carbidopa and levodopa for rapid onset of action, and ER pellets with levodopa for long-lasting efficacy” — and notes in the same release that patients on Crexont dosed an average of three times a day, versus five times a day for those on immediate-release carbidopa/levodopa.

Now back to that key number. From project initiation to filing, HRG2010’s cumulative R&D spend was approximately RMB 84.2 million.

For comparison: among Hengrui’s other filings this year, SHR-1918 injection (for homozygous familial hypercholesterolemia) disclosed cumulative R&D of about RMB 242 million, and SHR-A2009 (for EGFR-mutant non-small cell lung cancer) about RMB 330 million. HRG2010 cost roughly a third of the former and a quarter of the latter. Against a company that spent RMB 8.724 billion on R&D in 2025, this program is on the order of one-thousandth of the annual R&D budget.

The development path was equally frugal — three steps, done:

Registries differ slightly on Phase 3 start date: November 6, 2024 internationally; first-patient-in December 16, 2024 in China.

One combination of numbers deserves a pause: 165 patients, 84 centers — fewer than two patients per center on average.

By clinical-operations efficiency, that’s uneconomical — more centers means higher start-up and monitoring costs and greater data-consistency risk. But from another angle: for a product that will live or die on neurologists’ prescriptions, built by a company with almost no existing touchpoints in neurology, using one registrational study to build a relationship network across 84 hospitals led by a national-level key opinion leader — that changes the math completely.

For a company like Hengrui, which treats commercial capability as a core asset, this is a very typical move.

Now for the contrast.

Open Hengrui’s 2025 annual report and HRG2010 appears in exactly one place: item 1 under neuroscience in Appendix 8, the “key innovative product matrix” — a paragraph of text. Meanwhile, in the same report:

For contrast: febuxostat extended-release tablets — another improved ER formulation — appear in both the annual and interim clinical pipeline appendices, and made the 2027 expected-launch list.

An annual report published just over four months ago didn’t put it on the three-year launch forecast; five months later it filed. There’s no secret here, just a plain explanation: Hengrui’s disclosure volume on this asset runs far below its actual development pace.

This isn’t an oversight — it’s closer to a default classification habit. The H1 2026 interim report puts the taxonomy plainly: “the company has 26 Class 1 innovative drugs and 6 Class 2 new drugs approved in China” — Class 1 and Class 2 are two separate ledgers: Class 1 goes into the story; Class 2 goes into the product line. If approved, HRG2010 would be the 7th Class 2 new drug. It was never a shelved asset — it was just never the lead.

For analysts, there’s a takeaway: absence from a pipeline chart doesn’t mean a program is dead. For judging the true status of an improved-drug asset, R&D spend disclosures and regulatory filings are far more reliable than investor materials.

The Phase 3 comparator was carbidopa/levodopa extended-release tablets — originator Sinemet. From a regulatory standpoint the choice was exactly right: for an improved new drug to demonstrate clinical advantage, the cleanest approach is a head-to-head against the existing formulation of the same ingredients — and Hengrui did earn its “China’s first Phase 3 confirmatory study with carbidopa/levodopa ER tablets as active control” claim.

Commercially, the choice is a bit awkward.

Carbidopa/levodopa ER/CR tablets long had only the originator on sale in China, with supply crunches along the way. Domestic generics have been opening the gates in recent years: Shijiazhuang No.4 Pharma filed first in January 2023; per public reporting, Zhejiang Huahai followed as the second domestic maker, approved as a Category 4 generic and deemed to have passed consistency evaluation; Chongqing Huabang, Guangzhou Greens Cross and others are still in the review queue. By the time HRG2010 clears review and actually launches, its reference point will no longer be the scarce, expensive import of years past, but a product flattened by domestic generics with prices still drifting down.

More importantly, the pool was never big. China’s anti-Parkinson’s market has never been led by carbidopa/levodopa ER tablets, but by immediate-release levodopa/benserazide (Madopar), pramipexole, rasagiline, entacapone/levodopa combinations and the like. HRG2010 won in a small pool in Phase 3; what it needs to convert is the prescribing habit of a much bigger pool.

Many still picture Parkinson’s as a field of “old drugs ruling, nothing new for years.” By 2026 that picture is outdated. At launch, HRG2010 will face three forces at once.

Together the three forces send a clear message: HRG2010’s window isn’t open — it’s narrowing. Its relative edge is that it doesn’t change how patients take their medicine, only swapping tablets for capsules and bringing daily doses down (exactly how far down awaits the full data and final label) — and that is precisely the easiest kind of advantage to match.

This is the first question a company like Hengrui must answer for any single product, and HRG2010’s answer is split: the channel fit is excellent; the specialty-department foothold has to grow slowly out of those 84 centers.

The fit, first. Hengrui’s 2025 annual report discloses a marketing and sales force of about 9,000 (8,953 salespeople in the employee breakdown), a sales network covering over 25,000 hospitals and 200,000+ brick-and-mortar retail pharmacies across 30+ provincial-level regions in China, a specialty prescription-drug team covering all major online pharmacy platforms, plus a dedicated direct-to-patient (DTP) team. In early 2025 the company fully launched its “channel-building project,” explicitly aimed at covering the “last mile” of chronic-disease management and building an end-to-end chronic-care ecosystem.

Parkinson’s is precisely that kind of chronic disease: diagnosed and first prescribed in tier-3 hospital neurology departments, followed by a decade-plus of out-of-hospital refills and self-management, with dispensing concentrated in retail and primary care. This infrastructure is a natural fit for the product — and something small-to-mid-sized improved-drug companies simply cannot build.

Now the gaps. Hengrui has no marketed product in neurology. Its commercial experience in neuroscience centers on analgesia and anesthesia — the annual report lists the neuroscience focus areas as “analgesia and anesthesia,” neurodegenerative diseases, and stroke, while the marketed products serve anesthesiology and the perioperative setting, not neurology outpatient clinics. The ~9,000-strong force is configured for oncology, metabolism, immunology, and anesthesia.

Those 84 Phase 3 centers are Hengrui’s most tangible asset in this specialty. Converting research centers into prescribing centers takes post-marketing medical studies, academic conferences, and real-world data — and that machinery exists: the annual report discloses ~3,200 ongoing post-marketing medical research projects as of end-2025, covering a cumulative ~8,000 research centers, with 45 guidelines or consensuses citing company product evidence that year. Plugging HRG2010 into that machine is the highest-ROI move.

One more hard constraint to acknowledge. Hengrui’s 2026 sales plan states verbatim: “concentrate resources to push rapid hospital listing and access for innovative products,” with the full-year goal of “striving for innovative-drug sales revenue growth of over 30%.” In an organization where innovative-drug growth is the core KPI, a Class 2 new drug gets neither priority in the innovative-product hospital-listing queue nor a contribution to that growth curve — it will be structurally deprioritized. This isn’t about attitude; it’s decided by how performance is measured. To make it move, it needs an independent playbook that doesn’t compete with Class 1 products for resources.

Hengrui’s quality and supply system is more than equal to this product. The annual report states that all production lines for marketed products have passed GMP inspection, with ~20 overseas registration approvals covering injectables, oral formulations, and inhaled anesthetics, and products sold in 50+ countries; investor materials cite 12 advanced manufacturing plants. Carbidopa and levodopa are both mature APIs with a friendly cost structure — and domestic capacity carries special meaning for this category: China’s historical memory of it is precisely the imported originator going out of stock. “Stable supply” alone can be a line that moves neurologists.

The one technical point worth watching: for a multi-unit capsule with coexisting IR and ER units, whether release behavior stays consistent between clinical and commercial batches, and whether the dissolution profile holds up at scale. This class of product concentrates its process difficulty in coating and particle-size control. The two acceptance numbers (CXHS2600120, CXHS2600121) suggest at least two strengths were filed — the fuller the strength lineup, the easier for doctors to switch patients off multi-dose regimens. That’s both a commercial advantage and more process-consistency work.

HRG2010 is a mirror, reflecting a question every large domestic pharma faces in the same transition: when a company bets its entire narrative on innovation and globalization, where do you put the products that aren’t innovative, can’t go abroad, but genuinely solve concrete problems for Chinese patients?

Hengrui’s answer is already written in its actions — spending RMB 84.2 million, three studies, and 84 centers to quietly push it to the regulatory finish line, while giving it no leading role in any outward-facing material.

The real test ahead isn’t on the R&D side either. With a category whose global ceiling is barely over $300 million, a price anchor being flattened by generics, and a specialty where Hengrui has no existing foothold — how far this drug goes depends on whether those 84 centers convert from research relationships into prescribing relationships, and on whether the effect size holds up when the full data arrive.

Taking fewer pills a day is a real, tangible good for someone who has lived with Parkinson’s for over a decade. That good has now been carried all the way to filing. The remaining question: will a company with tens of billions in revenue, betting its growth on 30%+ innovative-drug growth, put a serious commercial playbook behind a product destined never to be the lead?